Nike Inc vs Tilray Brands Inc — how do they compare? Nike Inc trades at $34.65 (market cap $51.60B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Nike Inc is far larger — about 97.3× Tilray Brands Inc's market cap, and Nike Inc pays a 4.72% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nike Inc for 155 Days and Tilray Brands Inc for 31 Days on average.
| NKE | TLRY | |
|---|---|---|
Market Cap | $51.60B | $530.54M |
Volume | 43,506,062 | 9,099,075 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.68 | $21.00 |
52-Week Low | $33.87 | $3.57 |
Typical Hold Time | 155 Days | 31 Days |
Enterprise Value | $54.30B | $684.46M |
Dividend Yield | 4.72% | — |
Signals from Pluang's Aura AI — not financial advice
Nike's stock trades at $34.36, down 0.72% with a bearish technical outlook. The company reported $46.31B in revenue for 2025 with a 6.74% net margin, though earnings have beaten expectations in recent quarters. Analyst consensus remains positive with a $36.98 price target, while recent news highlights challenges in China and inventory management.
Nike faces near-term headwinds from slowing revenue growth and margin pressure, but strong brand positioning and consistent earnings beats provide upside potential. Key risks include consumer demand weakness and competitive pressures, while institutional sentiment remains cautiously optimistic for a turnaround.
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →